Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of GHZ339 in healthy volunteers
jRCT2071230087Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in None comparing GHZ339 single ascending dose with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Vital signs and 2 more. Started Nov 2023; status: completed.
02
Drugs
GHZ339
Beyond the preview
Go deeper on jRCT2071230087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230087.